Advertisement

Picture [iito] No Tracking 650x80px
Organisation › Details

Dewpoint Therapeutics (Group)

Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A. Founding investor Polaris Partners led the equity round and was joined by Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer. Dewpoint is harnessing recent insights into biomolecular condensates elucidated by founders Anthony Hyman of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden and Richard Young of the Whitehead Institute with the goal to uncover treatments for the toughest diseases. Biomolecular condensates have long been known but historically understudied because they are difficult to analyze with traditional drug discovery methods like protein crystallography and biochemical activity assays. Condensates are well-defined, membrane-less organelles found inside cells that take advantage of intrinsically disordered regions of proteins to organize certain proteins and nucleic acids in cells, bringing them together in high concentrations to significantly enhance the chemical reactions critical for the cells’ lives. Emerging understanding of condensates offers new insights into cellular function and disease that have not been considered by scientists and drug developers. *

 

Period Start 2019-01-30 existent
  Group Dewpoint Therapeutics (US)
  Predecessor Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG, Dresden)
Product Industry BIOTECH
Person Person Hyman, Anthony (Max Planck 201901 Group Leader at MPI-CBG Dresden + Co-Founder Dewpoint Therapeutics)
     
Region Region Boston, MA
  Country United States (USA)
  Street 6 Tide Street
Suite 300
  City 02210 Boston, MA
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Dewpoint Therapeutics. (1/30/19). "Press Release: Dewpoint Therapeutics Launches with $60 Million Series A to Advance Proprietary Platform for Drugging Condensates". Cambridge, MA.
     
   
Record changed: 2020-11-27

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top